Showing results (61-70 of 70) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cancer Science|November 12, 2013
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell countsTakaaki Ono, Akihiro Takeshita, Yuji Kishimoto, et al.Blood Advances|June 18, 2026
Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CMLNaoto Takahashi, Yosuke Minami, Yuki Fujioka, et al.Blood Advances|June 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIsTakaaki Ono, Takashi Okada, Naoto Takahashi, et al.Blood|September 23, 2022
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphomaKoji Izutsu, Shinichi Makita, Kisato Nosaka, et al.Blood Advances|July 5, 2024
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 studyItaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, et al.Journal of Hematology|September 9, 2024
Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic AnemiaHirofumi Yokota, Kotaro Miyao, Masashi Sawa, et al.British Journal of Haematology|July 9, 2026
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 studyNoriyoshi Iriyama, Naoto Takahashi, Katsumichi Fujimaki, et al.International Journal of Hematology|March 1, 2026
Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in JapanNaoto Takahashi, Shinya Kimura, Eri Matsuki, et al.Cancer Science|February 16, 2023
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01Naoko Hosono, SungGi Chi, Takahiro Yamauchi, et al.The Lancet. Haematology|November 26, 2021
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trialKazunori Murai, Hiroshi Ureshino, Takashi Kumagai, et al.Pageof 7